NXP Semiconductors N.V.
NXPINXP Semiconductors N.V. is coiled. The quarters are improving, yet the P/E sits at the 27th percentile of its own 4-year range — the business is moving before the market.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (8 weeks in) while the P/E sits at the 27th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +69.6% year on year, and 145% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
NXP Semiconductors N.V. trades at $219, building a base and 8 weeks into that stage. That is −10.5% against its own 200-day average. It sits at 22% of a 52-week range of $191 to $321. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (8 weeks and counting).
Today the stock is building a base — week 8 of stage 1. At $219 it trades −10.5% versus its 200-day average and sits at 22% of its 52-week range ($191–$321).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +177% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (8 weeks and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
NXP Semiconductors N.V. trades at 18.7× P/E, near the bottom of its own range — cheaper only 27% of the time. Its long-run median P/E is 21.2×, measured across 4.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 18.7× is near the bottom of its own range — cheaper only 27% of the time, against a long-run median of 21.2× measured over 4.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −17.4% against a −2.2% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +3.5%/yr price move, ~+3.5%/yr came from earnings growth and ~+0.0 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
NXP Semiconductors N.V. reads as turning around on its fundamental arc. Turning around — EPS growth swung from −21.6% at the trough to +39.7%, a 3-quarter improving streak, ROCE lifting at 19.2%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −2.7% | −2.4% | — | — |
| Profit | −17.7% | −5.7% | — | — |
| EPS | −17.4% | −4.8% | — | — |
| Stock price | −2.2% | +3.5% | +0.9% | +10.1% |
4-Factor Sector Score
52.0/100 — rank 10 of 27 in Semiconductors · 81% evidence confidence
NXP Semiconductors N.V. scores 52.0 out of 100 against the 27 companies it is compared with in Semiconductors, ranking 10. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.9 + 12.7 + 15.8 + 5.6 = 52. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
NXP Semiconductors N.V. reported $3.5 B of revenue in the Jun 26 quarter, +19.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at 2.6% a year. The last full year, FY25, came in at $12.3 B. The last four reported quarters add to $13.2 B.
FY25 revenue came in at $12.3 B (−2.7% on the year), capping 4 years at 2.6% compound. The latest quarter (Jun 26) printed $3.5 B, +19.5% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +9.1% growth against the decade's 2.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.7% over the last 4 quarters against +0.3%/yr over the last 8 — accelerating; TTM profit +37.7% vs +4.2%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
NXP Semiconductors N.V.'s operating margin is 30.6% in the Jun 26 quarter, +7.1 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 23.3% to 30.8%. The current quarter sits inside that band.
The latest quarter's operating margin is 30.6%, +7.1 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 23.3%–30.8%.
Why the margin moved: operating margin went +7.1 pp year on year while gross margin went +3.9 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
NXP Semiconductors N.V. earned $0.8 B of net profit in the Jun 26 quarter, +69.6% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $2.4 B. The 4-year compound rate is 5.5%. That is 22.3% of the quarter's revenue. The same quarter a year earlier earned $0.5 B.
Jun 26 profit was $0.8 B, +69.6% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $2.4 B (−17.7%), and the 4-year compound rate is 5.5%.
Why profit moved: revenue contributed +19.5% and the margin +7.1 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +44.2% vs revenue +9.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 145% of NXP Semiconductors N.V.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $4.0 B of operating cash against $2.4 B of profit. After $0.4 B of capital spending, $3.6 B was left as free cash.
FY25: operating cash of $4.0 B against reported profit of $2.4 B, leaving free cash of $3.6 B after $0.4 B of capital spending. Across the last 3 fiscal years the conversion rate is 145% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
NXP Semiconductors N.V. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
NXP Semiconductors N.V. earns a ROE of 16% in FY25. Return on invested capital clears the cost of that capital by +5.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 19.3% net margin on 0.40× asset turns.
FY25 ROE is 16%.
Why the return is what it is — the wiring (FY25): 19.3% net margin × 0.40× asset turns × 2.12× balance-sheet leverage ≈ 16.4% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 18.0% − 12.5% = a +5.5 pp spread. The 12.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
NXP Semiconductors N.V. paid $4.06 per share over the last four reported quarters. The most recent declaration was $1.01 for Jun 26. Against the current price of $219 that is a trailing yield of 1.85%, measured on dividends already paid rather than on a forecast.
NXP Semiconductors N.V. paid $4.06 per share across the last four reported quarters, most recently $1.01 for Jun 26. Against the current price of $219 the trailing twelve months work out to 1.85% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
NXP Semiconductors N.V. carries total debt of $11.0 B against shareholder equity of $11.8 B as of Jun 26, a debt-to-equity of 0.93. On the annual view that ratio went from 1.13 in FY21 to 0.84 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $11.0 B against shareholder equity of $11.8 B — a debt-to-equity of 0.93. On the annual view, debt-to-equity went from 1.13 (FY21) to 0.84 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for NXP Semiconductors N.V., so this section names the gap rather than filling it. At typical trading volumes those positions would take about 2.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
NXP Semiconductors N.V.: the Z-score reads 3.58. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.58 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.58.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Micron Technology, Inc.MU | 73.7/100Favorable setup71% evidence | FADING | 29.0/35 Revenue 100% · PAT 100% · OPM change 57.1 pp 83% evidence | 19.2/25 ROCE 51.7% · OPM 80.4% 76% evidence | 11.5/20 P/E 20.6× · PEG — 15% evidence | 14.0/20 RS sector 44.4% · RS bench 59.7% · 1Y 469.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 19.2 + 11.5 + 14 = 73.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Analog Devices, Inc.ADI | 67.9/100Favorable setup85% evidence | ASLEEP | 28.7/35 Revenue 33.6% · PAT 100% · OPM change 10.9 pp 95% evidence | 16.6/25 ROCE 11.6% · OPM 39.5% 76% evidence | 12.2/20 P/E 43.3× · PEG 1.33 65% evidence | 10.4/20 RS sector -14.9% · RS bench 3% · 1Y 47.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 28.7 + 16.6 + 12.2 + 10.4 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Advanced Micro Devices, Inc.AMD | 67.6/100Favorable setup71% evidence | ASLEEP | 27.2/35 Revenue 39.5% · PAT 100% · OPM change 19 pp 83% evidence | 12.9/25 ROCE 9% · OPM 17.3% 76% evidence | 9.3/20 P/E 132.2× · PEG — 15% evidence | 18.2/20 RS sector 28.9% · RS bench 48.2% · 1Y 225.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 12.9 + 9.3 + 18.2 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4NVIDIA CorporationNVDA | 67.3/100Favorable setup85% evidence | TURNING | 20.4/35 Revenue 83.4% · PAT 100% · OPM change 5.4 pp 95% evidence | 21.6/25 ROCE 71.3% · OPM 66.2% 76% evidence | 15.2/20 P/E 26× · PEG 0.77 65% evidence | 10.1/20 RS sector -17.5% · RS bench 2.6% · 1Y 21.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 21.6 + 15.2 + 10.1 = 67.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Broadcom Inc.AVGO | 62.2/100Mixed-positive evidence85% evidence | ASLEEP | 30.0/35 Revenue 48.7% · PAT 100% · OPM change 16.1 pp 95% evidence | 20.4/25 ROCE 26% · OPM 54.3% 76% evidence | 5.9/20 P/E 48.4× · PEG 5.06 65% evidence | 5.9/20 RS sector -29.7% · RS bench -12.5% · 1Y -1.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 20.4 + 5.9 + 5.9 = 62.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -29.7% and the one-year return is -1.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Texas Instruments IncorporatedTXN | 62.0/100Mixed-positive evidence81% evidence | ASLEEP | 20.9/35 Revenue 16.7% · PAT 20% · OPM change 7.6 pp 83% evidence | 20.5/25 ROCE 22.7% · OPM 42.6% 76% evidence | 9.2/20 P/E 45.1× · PEG 2.24 65% evidence | 11.4/20 RS sector -10.4% · RS bench 7.3% · 1Y 45.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 20.5 + 9.2 + 11.4 = 62 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Silicon Motion Technology CorporationSIMO | 60.8/100Thin evidence · provisional56% evidence | ASLEEP | 22.5/35 Revenue — · PAT — · OPM change 9.4 pp 39% evidence | 14.0/25 ROCE 10.3% · OPM 15.3% 76% evidence | 10.8/20 P/E 39.1× · PEG — 15% evidence | 13.5/20 RS sector 17.5% · RS bench 32.5% · 1Y 161.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 14 + 10.8 + 13.5 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Credo Technology Group Holding LtdCRDO | 53.0/100Mixed-positive evidence71% evidence | ASLEEP | 26.5/35 Revenue 100% · PAT 100% · OPM change 15.8 pp 83% evidence | 12.9/25 ROCE 11.1% · OPM 35.7% 76% evidence | 9.9/20 P/E 73.5× · PEG — 15% evidence | 3.7/20 RS sector -25.5% · RS bench -10.5% · 1Y -4.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 12.9 + 9.9 + 3.7 = 53 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -25.5% and the one-year return is -4.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 9Marvell Technology, Inc.MRVL | 52.2/100Mixed-positive evidence67% evidence | FADING | 17.9/35 Revenue 30.6% · PAT — · OPM change 1.8 pp 71% evidence | 9.6/25 ROCE 6.3% · OPM 16.7% 76% evidence | 10.1/20 P/E 62.2× · PEG — 15% evidence | 14.6/20 RS sector 34.3% · RS bench 52% · 1Y 209.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 9.6 + 10.1 + 14.6 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10NXP Semiconductors N.V.this pageNXPI | 52.0/100Mixed-positive evidence81% evidence | BASING | 17.9/35 Revenue 8.8% · PAT 38.4% · OPM change 7.1 pp 83% evidence | 12.7/25 ROCE 4.9% · OPM 30.6% 76% evidence | 15.8/20 P/E 23.6× · PEG 0.6 65% evidence | 5.6/20 RS sector -29.5% · RS bench -13.4% · 1Y -2.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 12.7 + 15.8 + 5.6 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Astera Labs, Inc.ALAB | 51.6/100Mixed-positive evidence71% evidence | ASLEEP | 21.8/35 Revenue 98.7% · PAT 100% · OPM change 2 pp 83% evidence | 9.9/25 ROCE 6.1% · OPM 22.7% 76% evidence | 8.8/20 P/E 239.1× · PEG — 15% evidence | 11.1/20 RS sector -0.5% · RS bench 16.1% · 1Y 9.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 9.9 + 8.8 + 11.1 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12QUALCOMM IncorporatedQCOM | 50.7/100Mixed-positive evidence81% evidence | ASLEEP | 5.8/35 Revenue 1.9% · PAT -20% · OPM change -9 pp 83% evidence | 18.3/25 ROCE 22.6% · OPM 18.5% 76% evidence | 16.4/20 P/E 21.6× · PEG 0.44 65% evidence | 10.2/20 RS sector -17.2% · RS bench 2.5% · 1Y 10.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 5.8 + 18.3 + 16.4 + 10.2 = 50.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Microchip Technology IncorporatedMCHP | 49.9/100Mixed-negative evidence74% evidence | ASLEEP | 21.8/35 Revenue 20.9% · PAT — · OPM change 19.7 pp 62% evidence | 9.4/25 ROCE 2.5% · OPM 22.7% 76% evidence | 12.9/20 P/E 136.1× · PEG 0.78 65% evidence | 5.8/20 RS sector -28% · RS bench -12.1% · 1Y 6.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 9.4 + 12.9 + 5.8 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Tower Semiconductor Ltd.TSEM | 48.9/100Mixed-negative evidence81% evidence | ASLEEP | 20.4/35 Revenue 14.9% · PAT 50.5% · OPM change 8.9 pp 83% evidence | 11.7/25 ROCE 2.9% · OPM 19.6% 76% evidence | 7.6/20 P/E 103× · PEG 2.27 65% evidence | 9.2/20 RS sector -2% · RS bench 13% · 1Y 201.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 11.7 + 7.6 + 9.2 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Qorvo, Inc.QRVO | 48.9/100Mixed-negative evidence71% evidence | TURNING | 17.1/35 Revenue -0.2% · PAT 100% · OPM change 8.6 pp 83% evidence | 6.6/25 ROCE 1.9% · OPM 12.3% 76% evidence | 11.3/20 P/E 21.8× · PEG — 15% evidence | 13.9/20 RS sector -4% · RS bench 19.6% · 1Y 24.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6.6 + 11.3 + 13.9 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16MACOM Technology Solutions Holdings, Inc.MTSI | 48.9/100Mixed-negative evidence68% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 7.8 pp 45% evidence | 15.9/25 ROCE 13% · OPM 23.3% 76% evidence | 5.8/20 P/E 102.1× · PEG 2.95 65% evidence | 5.1/20 RS sector -17.3% · RS bench -2.6% · 1Y 98%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 15.9 + 5.8 + 5.1 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Intel CorporationINTC | 47.2/100Mixed-negative evidence64% evidence | ASLEEP | 18.8/35 Revenue 7.5% · PAT — · OPM change 16 pp 62% evidence | 6.7/25 ROCE 2.7% · OPM 12.2% 76% evidence | 8.5/20 P/E 837.3× · PEG — 15% evidence | 13.2/20 RS sector 23.1% · RS bench 38.8% · 1Y 241.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 6.7 + 8.5 + 13.2 = 47.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Skyworks Solutions, Inc.SWKS | 46.0/100Thin evidence · provisional56% evidence | TURNING | 13.8/35 Revenue — · PAT — · OPM change -7 pp 39% evidence | 6.8/25 ROCE 0.7% · OPM 4.5% 76% evidence | 10.9/20 P/E 32.4× · PEG — 15% evidence | 14.5/20 RS sector -3.7% · RS bench 20.8% · 1Y 8.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 6.8 + 10.9 + 14.5 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Lattice Semiconductor CorporationLSCC | 45.4/100Thin evidence · provisional56% evidence | ASLEEP | 20.7/35 Revenue — · PAT — · OPM change 11.5 pp 39% evidence | 9.9/25 ROCE 3.4% · OPM 15.3% 76% evidence | 8.6/20 P/E 678.7× · PEG — 15% evidence | 6.2/20 RS sector -16.8% · RS bench -1.2% · 1Y 47.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 9.9 + 8.6 + 6.2 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20SiTime CorporationSITM | 44.7/100Thin evidence · provisional51% evidence | ASLEEP | 20.5/35 Revenue 65.2% · PAT — · OPM change 35.7 pp 40% evidence | 5.4/25 ROCE -1.2% · OPM -10.9% 57% evidence | 9.7/20 P/E 98.7× · PEG — 15% evidence | 9.1/20 RS sector -5.2% · RS bench 10.5% · 1Y 75.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 5.4 + 9.7 + 9.1 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Semtech CorporationSMTC | 44.5/100Mixed-negative evidence64% evidence | TURNING | 11.0/35 Revenue 14.3% · PAT — · OPM change -5.4 pp 62% evidence | 5.4/25 ROCE 2.2% · OPM 8.9% 76% evidence | 9.0/20 P/E 218.7× · PEG — 15% evidence | 19.1/20 RS sector 31.3% · RS bench 53.8% · 1Y 175.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 5.4 + 9 + 19.1 = 44.5 · Decision use: Price leads the evidence: RS versus the benchmark is 53.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Monolithic Power Systems, Inc.MPWR | 42.8/100Mixed-negative evidence81% evidence | ASLEEP | 17.6/35 Revenue 28.6% · PAT -56.8% · OPM change 6.2 pp 83% evidence | 13.9/25 ROCE 7.8% · OPM 31% 76% evidence | 5.6/20 P/E 84.6× · PEG 3.59 65% evidence | 5.7/20 RS sector -25.6% · RS bench -9.9% · 1Y 25.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 13.9 + 5.6 + 5.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23STMicroelectronics N.V.STM | 40.0/100Mixed-negative evidence64% evidence | ASLEEP | 17.8/35 Revenue 10.5% · PAT -27% · OPM change 10.2 pp 62% evidence | 5.7/25 ROCE 0.8% · OPM 5.4% 76% evidence | 9.1/20 P/E 139.1× · PEG — 15% evidence | 7.4/20 RS sector -6.1% · RS bench 7.9% · 1Y 72.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 5.7 + 9.1 + 7.4 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Arm Holdings plcARM | 39.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.7/35 Revenue 25.1% · PAT 49.4% · OPM change -3.2 pp 83% evidence | 10.4/25 ROCE 8.9% · OPM 7.6% 76% evidence | 3.7/20 P/E 362.7× · PEG 7.72 65% evidence | 10.8/20 RS sector 2% · RS bench 17.6% · 1Y 70.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 10.4 + 3.7 + 10.8 = 39.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Rambus Inc.RMBS | 38.7/100Thin evidence · provisional56% evidence | ASLEEP | 14.5/35 Revenue — · PAT — · OPM change -3.6 pp 39% evidence | 12.2/25 ROCE 5% · OPM 34.3% 76% evidence | 10.2/20 P/E 60.9× · PEG — 15% evidence | 1.8/20 RS sector -41.8% · RS bench -28% · 1Y -20.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 12.2 + 10.2 + 1.8 = 38.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26ON Semiconductor CorporationON | 37.8/100Thin evidence · provisional56% evidence | ASLEEP | 16.8/35 Revenue — · PAT — · OPM change 2.9 pp 39% evidence | 8.4/25 ROCE 2.2% · OPM 16.1% 76% evidence | 10.3/20 P/E 58.5× · PEG — 15% evidence | 2.3/20 RS sector -27.1% · RS bench -13.8% · 1Y 30.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 8.4 + 10.3 + 2.3 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27GLOBALFOUNDRIES Inc.GFS | 29.9/100Adverse evidence64% evidence | ASLEEP | 11.7/35 Revenue 1.4% · PAT — · OPM change -1.9 pp 62% evidence | 7.5/25 ROCE 1.2% · OPM 9.7% 76% evidence | 10.0/20 P/E 64.4× · PEG — 15% evidence | 0.7/20 RS sector -31.4% · RS bench -18.8% · 1Y 30.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 7.5 + 10 + 0.7 = 29.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is NXP Semiconductors N.V.'s stock price today?
NXP Semiconductors N.V. trades at $219, −2.2% over the past year. The company is valued at $55.0 B. The stock sits at 22% of its 52-week range of $191–$321, −10.5% versus its 200-day average. On the tape, the price is building a base, 8 weeks in. — as of 17 September 2026.
What were NXP Semiconductors N.V.'s latest quarterly results?
NXP Semiconductors N.V. reported revenue of $3.5 B and net profit of $0.8 B for the Jun 26 quarter. Revenue rose 19.5% and profit rose 69.6% year on year. Earnings per share were $3.02. The operating margin was 30.6%, 7.1 pp higher than a year earlier. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s revenue?
NXP Semiconductors N.V. reported revenue of $3.5 B in the Jun 26 quarter, +19.5% year on year. For the full FY25 fiscal year, revenue was $12.3 B (−2.7%). Over the last 4 years revenue compounded at 2.6% a year. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s profit?
NXP Semiconductors N.V. earned $0.8 B of net profit in the Jun 26 quarter, +69.6% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $2.4 B. The operating margin ran 30.6% in the latest quarter. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s market cap?
NXP Semiconductors N.V.'s market capitalisation is $55.0 B at a stock price of $219. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s P/E ratio?
NXP Semiconductors N.V. trades at a P/E of 18.7×, at the 27th percentile of its own 4-year range, against a long-run median of 21.2×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does NXP Semiconductors N.V. pay a dividend?
Yes — NXP Semiconductors N.V. declared $1.01 per share for Jun 26, and $4.06 per share across the last four reported quarters. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s dividend per share?
NXP Semiconductors N.V.'s most recently declared dividend is $1.01 per share for Jun 26, giving $4.06 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s dividend yield?
NXP Semiconductors N.V.'s trailing dividend yield is 1.85%: $4.06 declared per share across the last four reported quarters, against a share price of $219. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is NXP Semiconductors N.V. overvalued?
On its own history, NXP Semiconductors N.V. looks cheap: its P/E of 18.7× has been cheaper only 27% of the time in 4 years (long-run median 21.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is NXP Semiconductors N.V. growing?
Yes — NXP Semiconductors N.V. is growing: latest-quarter revenue +19.5% year on year, profit +69.6%, and the margin +7.1 pp at 30.6%. The 4-year compound rates are 2.6% (revenue) and 5.5% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is NXP Semiconductors N.V. performing?
NXP Semiconductors N.V. is building a base, 8 weeks in. Its latest quarter's revenue rose 19.5% and profit rose 69.6% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is NXP Semiconductors N.V. in?
Turning around — EPS growth swung from −21.6% at the trough to +39.7%, a 3-quarter improving streak, ROCE lifting at 19.2%. The read comes from the last 12 quarters of growth (revenue growth +8.7% latest, profit growth +37.7% latest, eps growth +39.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is NXP Semiconductors N.V. in an uptrend?
No — the price is building a base (week 8 of stage 1), trading −10.5% versus its 200-day average and at 22% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is NXP Semiconductors N.V. beating the market?
Not lately — on a trailing-13-week view NXP Semiconductors N.V. is currently behind the S&P 500 (8 weeks and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +177% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will NXP Semiconductors N.V.'s stock price go up?
This page publishes no price forecast for NXP Semiconductors N.V. What it measures instead: the stock price is $219, the price is building a base 8 weeks in. Its P/E of 18.7× sits at the 27th percentile of its own 4-year range. — as of 17 September 2026.
Does NXP Semiconductors N.V. have too much debt?
It is moderate — NXP Semiconductors N.V.'s debt-to-equity is 0.93. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is NXP Semiconductors N.V.'s capex?
NXP Semiconductors N.V. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.4 B. — as of 17 September 2026.
What is NXP Semiconductors N.V.'s cash flow?
NXP Semiconductors N.V. generated $4.0 B of operating cash flow in FY25 and $3.6 B of free cash flow after $0.4 B of capital spending. Reported profit that year was $2.4 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is NXP Semiconductors N.V.'s profit real cash?
Yes — over the last 3 fiscal years, 145% of NXP Semiconductors N.V.'s reported profit arrived as operating cash. In FY25, operating cash was $4.0 B against reported profit of $2.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is NXP Semiconductors N.V.?
On the balance sheet, the Z-score reads 3.58 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is NXP Semiconductors N.V. in its business cycle?
NXP Semiconductors N.V.'s FY25 operating margin was 27.7%, against a 5-year band of 23.3%–30.8%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 30.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the NXP Semiconductors N.V. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is NXP Semiconductors N.V. a stock worth studying right now?
This is not investment advice. The machine read: NXP Semiconductors N.V. is coiled. The quarters are improving, yet the P/E sits at the 27th percentile of its own 4-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!